36
Participants
Start Date
July 5, 2022
Primary Completion Date
September 4, 2025
Study Completion Date
September 16, 2026
Nipocalimab
Nipocalimab will be administered intravenously in double-blind period and LTE period.
Placebo
Nipocalimab matching placebo will be administered intravenously in double-blind period.
Glucocorticoids
Prednisone or equivalent will be administered orally as Glucocorticoid.
Orszagos Mozgasszervi Intezet ORFI Campus, Budapest
Debreceni Egyetem, Debrecen
Charite Universitaetsmedizin Berlin, Berlin
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City
Immanuel Klinik Rüdersdorf, Rüdersdorf Bei Berlin
Ajou University Hospital, Suwon
University of Pennsylvania - Perelman School of Medicine, Philadelphia
IRCSS Ospedale San Raffaele Turro, Milan
Johns Hopkins University, Baltimore
Fondazione IRCCS Policlinico San Matteo, Pavia
Hosp. Univ. de La Paz, Madrid
ACME Research Arthritis and Osteoporosis Center, Orangeburg
Augusta University, Augusta
Integral Rheumatology And Immunology Specialists, Plantation
FM Clinical Research, LLC South Florida Neurology Associates, P. A., Boca Raton
University of South Florida, Tampa
Hosp. Univ. Marques de Valdecilla, Santander
Wexner Medical Center at the Ohio State University, Columbus
Centro Integral en Reumatologia S A de C V, Guadalajara
Centro de Estudios de Investigacion Basica y Clinica, S.C., Guadalajara
Clinical Research Institute of Michigan, LLC, Saint Clair Shores
A.O. Universitaria Ospedali Riuniti di Ancona, Ancona
University of Kansas Medical Center, Kansas City
Nouvel Hopital Civil, Strasbourg
Hôpital Pitié-Salpétrière, Paris
Nervie and Muscle Center of Texas, Houston
University of Texas at Houston Medical School, Houston
Klinikum der Universitaet Muenchen, München
Arizona Arthritis and Rheumatology Research PLLC, Phoenix
HonorHealth Neurology, Scottsdale
Attune Health Autoimmune and Inflamation Care and Research, Beverly Hills
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance
University of California Irvine Medical Center, Orange
Oregon Health and Science University, Portland
The Brigham and Women's Hospital, Inc., Boston
Lawson Health Research / London Health Sciences Center Research, London
AMIR Research, Montreal
Revmatologicky ustav, Prague
Hospital Pasteur, Nice
Fondazione Policlinico Universitario A Gemelli IRCCS, Roma
National Hospital Organization Kyushu Medical Center, Fukuoka
Fukushima Medical University Hospital, Fukushima
St Marianna University Hospital, Kanagawa
National Hospital Organization Osaka Minami Medical Center, Kawachi-Nagano
Tokushukai Chiba-Nishi General Hospital, Matsudo-shi
Shinshu University Hospital, Matsumoto
Tohoku University Hospital, Sendai
St. Luke's International Hospital, Tokyo
Nippon Medical School Hospital, Tokyo
CITER Centro de Investigacion y Tratamiento de las Enfermedades Reumaticas S A de C V, México
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Bydgoszcz
Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher, Warsaw
Seoul National University Hospital, Seoul
Hosp. Univ. de Bellvitge, Barcelona
Western General Hospital, Edinburgh
University College London Hospitals NHSFT, London
Salford Royal Hospital, Salford
Janssen Research & Development, LLC
INDUSTRY